FILTER

FILTERED INTERVIEW RESULTS

Peter De Leo

MANAGING DIRECTOR, LYCOPODIUM LIMITED
"Lycopodium is busier than ever, particularly in Africa, where we have 10 projects, in addition to about 10 other feasibility studies underway."

Andrew Maatla Motsomi

MANAGING DIRECTOR, DEBSWANA
"The current trend of rare discoveries has created great excitement in the market, leading to record value purchases."

Mouhamed Kebe

MANAGING PARTNER, GENI & KEBE
"African governments are becoming more aware of the need to create a fair balance of interests between the state and investors."

Liam Morrissey

CEO, MS RISK
"The real danger is that some companies may still want to trade off the old business model of six years ago."

Sébastien de Montessus

PRESIDENT & CEO, ENDEAVOUR MINING
"Last year, we announced our goal to discover between 15 and 20 million oz Au by 2026. We are making good progress towards this goal with over 250,000 m drilled already this year."

Ralph Heath & Ernest Krakani

MANAGING DIRECTOR: EARTH AND ENVIRONMENT, WSP IN AFRICA & COUNTRY LEAD FOR GOLDER│WSP IN GHANA / WEST AFRICA
The Golder team grew from 7,000 to over 61,000 people around the world.

Cedric Fernandez

MANAGING DIRECTOR AFRICA POWER SERVICES
"There is no miner or junior that is not considering hybridizing existing or new power stations by adding more renewables into the mix."

Kwame Amponsah

GENERAL MANAGER, RAMOTH SERVICES
Ramoth Services supports mines with engineering and construction in Ghana.

Marc-Antoine Audet

CEO, SAMA RESOURCES
Sama Resources is exploring for nickel, copper and graphite in West Africa

NanaAma Botchway

MANAGING PARTNER, N. DOWUONA & COMPANY
N. Dowuona & Company is a predominantly female-owned and led law firm in Ghana and describes regulatory conditions for mining.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS